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Abstract
The hyper-IgE syndromes are rare, complex primary immunodeficiencies characterized by clinical manifestation
diversity, by particular susceptibility to staphylococcal and mycotic infections as well as by a heterogeneous
genetic origin. Two distinct entities - the classical hyper-IgE syndrome which is inherited in an autosomal dominant
pattern and the autosomal recessive hyper-IgE syndrome have been recognized. The autosomal dominant hyper-
IgE syndrome is associated with a cluster of facial, dental, skeletal, and connective tissue abnormalities which are
not observable in the recessive type. In the majority of affected patients with autosomal dominant hyper-IgE
syndrome a mutation in the signal transducer and the activator of the transcription 3 gene has been identified,
leading to an impaired Th17 cells differentiation and to a downregulation of an antimicrobial response. A mutation
in the dedicator of the cytokinesis 8 gene has been identified as the cause of many cases with autosomal recessive
hyper-IgE syndrome and, in one patient, a mutation in tyrosine kinase 2 gene has been demonstrated. In this
paper, the authors provide a review of the clinical manifestations in the hyper-IgE syndromes with particular
emphasis on the diversity of their phenotypic expression and present current diagnostic guidelines for these
diseases.
Introduction
The hyper-IgE syndrome (HIES) was first described in
1966 by Davis, Wedgwood and Schaller [1]; the authors
perceived the similarity of severe dermatitis associated
with “cold” abscesses with the disease attributed to the
prophet Job and hence designated it “Job’sS y n d r o m e ”.
In 1972, Buckley and colleagues reported infectious
complications in two children who presented with
severe chronic dermatitis, coarse faces, and an increased
concentration of serum immunoglobulin E; hence these
manifestations were termed “Buckley’sS y n d r o m e ” [2].
Further investigations revealed that increased IgE con-
centrations and defective neutrophil chemotaxis [3] are
recognized in Job’s syndrome as well as in Buckley’s
syndrome, being the same disease entity. In the 1970s, a
manifestation of the immune defect in HIES resulted in
its inclusion in the group of primary immunodeficiency
diseases by Hill et al [4], and the term “Hyper-IgE
Recurrent Infection Syndrome” (HIERIS) as proposed by
Buckley was also accepted [5]. Extensive reviews of the
syndrome were presented in 2000 by Erlewyne-Lajeu-
nesse [6] and in 2005 by Grimbacher and colleagues [7];
furthermore, discussions on the disease chaired by Free-
man and Holland have been recently published [8,9].
Although the first data concerning the prevalence of
hyper-IgE syndrome referred only to the Caucasian race,
further reports indicate its occurence among the Asian
and African populations [10,11]; the syndrome occurs in
equal frequency among males and females.
Several manifestations of the hyper-IgE syndrome con-
sist of a clinical symptomatology of related diseases,
leading to diagnostic difficulties, particularly in young
patients and in atypical less severe cases [12] and the
diagnosis of pediatric hyper-IgE syndrome is a compila-
tion of symptoms expressed in the later years of
patient’s life [7].
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ciency with diverse clinical manifestations and heteroge-
neous genetic origins [13]. Recent studies have
demonstrated that hypomorphic mutations in the signal
transducer and the activator of transcription 3 (STAT3)
gene result in the classical multisystemic, autosomal
dominant form of HIES, associated with facial, dental,
skeletal, and connective tissue abnormalities [14-16]. A
STAT3 mutation results in a defective multiple cytokine
signal transduction, including interleukin (IL)-6 and IL-
22, leading to impaired Th17 function and thus explain-
ing the susceptibility to infections in HIES.
In 2004 Renner et al [17] reported an autosomal
recessive form of the hyper-IgE syndrome, sharing
common features with autosomal dominant HIES, such
as hyperimmunoglobulinemia E, susceptibility to sta-
phylococcal infections and cutaneous lesions. However,
a different infection profile, a high rate of neurological
complications, as well as frequently reported autoim-
munity and malignancy, suggest a distinct disease
entity. Initially, in a single patient with autosomal
recessive HIES, a null mutation in the tyrosine kinase
2( TYK2) gene was identified. The Tyk2 deficiency is
responsible for both innate and adaptive impaired
immune responses due to defective cytokine signal
transduction pathways which depend on interferon
(IFN)-a, IL-6, IL-10, IL-12, and IL-23 [18]. In many,
although not all cases of autosomal recessive HIES,
homozygous mutations of dedicator of cytokinesis gene
(DOCK8) has been demonstrated, leading to the dis-
ruptive production of a protein involved in the regula-
tion of the actin skeleton [19].
Clinical presentation
Autosomal dominant HIES
The clinical triad of symptoms found generally in 75%
of all cases of AD-HIES and in 85% of patients over 8
years old includes: 1) recurrent staphylococcal abscesses,
2) recurrent airway infections, 3) increased concentra-
tion of immunoglobulin E in serum [7]. It has been
stressed in the literature that neonatal rash is typically
the first clinical manifestation of the hyper-IgE syn-
drome [20,21]. Interestingly, although chronic dermatitis
in the hyper-IgE syndrome is traditionally described as
eczema, it is doubtful if this rash really presents as ato-
pic dermatitis [22-24], particularly given that skin biop-
sies reveal eosinophilic infiltration related to that
observed in eosinophilic folliculitis [25]. Skin infections
also occur frequently - furunculosis and cellulitis may
be observed early on in infancy. “Cold” abscesses, typi-
cally observed in patients who are not on antibiotic pro-
phylaxis, are pathognomonic for the hyper-IgE
syndrome, but are not necessary for a definitive diagno-
sis [26,27]. Severe recurrent respiratory infections are
usually caused by Staphylococcus aureus,i n c l u d i n g
MRSA [28] and, less frequently, by Haemophilus influen-
zae and Streptococcus pneumoniae. Pneumonias are typi-
cally complicated by lung abscesses [29], bronchiectases,
bronchopleural fistulas and the formation of pneumato-
cele [6,30] (Figure 1). These bronchopulmonary lesions
are predisposing factors for colonization by opportunis-
tic microorganisms such as Pseudomonas aeruginosa
and Aspergillus fumigatus. The latter can lead not only
to invasive aspergillosis requiring intensive therapy, but
also to the formation of aspergilloma (Figure 2). Pul-
monary sequelae lead invariably to the development of
chronic respiratory insufficiency and are the main cause
of mortality in HIES. Hemoptysis complicating lung
abscess and cystic lung disease are the next common
cause of death in HIES reported by Freman et al [31].
Upper airway infections manifest as paranasal sinusitis,
exsudative otitis media [32], otitis externa and mastoidi-
tis. In approximately 80% of all cases, mycotic infections
of the skin and mucous membranes with Candida albi-
cans and other fungal strains may coexist [7]. There are
also reports concerning Pneumocystis jiroveci infection
[33,34], cryptococcosis [35,36], histoplasmosis [37-39],
disseminated pulmonary candidiasis [40], Mycobacter-
ium intracellulare and Nocardia infection [12], as well
as post-BCG vaccination complications [12,41,42]. In
the autosomal dominant form of hyper-IgE syndrome,
infections with herpes simplex virus are relatively infre-
quent [43].
In the majority of affected individuals, characteristic
constitutional features are noticeable, such as a coarse
face, rough skin, deep-set eyes, a prominent forehead,
prognathism (Figure 3), thick lower lip and auricles, a
wide nose and increased interalar distance [1,2,34,44,45].
There are also reports concerning mid-face anomalies,
an arched palate [34] and a rare malformation - cranio-
synostosis [46-48]. Characteristic oral and dental mani-
festations occurring in HIES include the delayed loss of
primary teeth, which occurred in 71% of children over
the age of eight years in the study by Grimbacher et al
[34], the abnormal development of permanent teeth
[34,49], severe dental caries with periapical abscesses
formation [50] (Figure 4) and periodontitis [51].
Recurrent pathological bone fractures reflecting the
multisystemic involvement in the hyper-IgE syndrome
are noted in more than 50% of patients [7]. Typically,
long bones are affected [52], as well as ribs, and, less
frequently, the vertebral column may also be involved
[34]; these fractures occur frequently as a result of
minor injuries. Brestel et al [53] described a pediatric
HIES case displayng a rare association with osteogenesis
imperfecta tarda. In the group of six patients in whom
osteopenia was revealed initially using radiology [54]
and subsequently by photon absorptiometry [55], three
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estingly, decreased bone mineral density is not a predis-
posing factor for the pathological fractures. Grimbacher
et al [34] showed diminished bone density in a group of
five out of nine patients, in whom densitometry was car-
ried out, yet pathological bone fractures occurred in two
patients with abnormal results of this examination and
in three patients with normal bone mineral density. It
has been suggested that osteopenia may result from
excessive bone resorption caused by monocytes and
activity of prostaglandin E2 [55]; moreover, cytokine
profile in the hyper-IgE syndrome influences bone
resorption, similar to women in the postmenopausal
period [56]. Minegishi et al demonstrated that osteo-
clasts from HIES patients with STAT3 mutations show
higher bone resorption activity compared with those
from control subjects [57]. More than 60% of affected
individuals present with scoliosis of varying degrees of
severity and of different origin. This may be a result of
different longitudinal dimension of the lower limbs, of
thoracotomy for the purpose of removing pneumatocele,
and of vertebral column anomalies [7], which, together
with joint hyperextensibility, are another part of the
hyper-IgE puzzle [46-48].
In patients with HIES, ocular complications were
noted as well, including extensive xanthelasmas [58],
giant chalasias [59,60], undefined eyelid nodules [61],
strabismus [62], and retinal detachment with compli-
cated cataracts [63].
The hyper-IgE syndrome brings about an increased
risk of autoimmune diseases, among them systemic
lupus erythemathosus [64-66], dermatomyositis [67],
and membranoproliferative glomerulonephritis [68].
An increased incidence of lymphoproliferative disor-
ders has also been noted, particularly of non-Hodgkin
lymphomas [58,69-72] and of Hodgkin disease [73,74].
Oztop and colleagues diagnosed pulmonary adenocarci-
noma in a patient with HIES [75].
Ling et al [76] reported coronary artery aneurysms
and ectasias identified with cardiac catheterization in
two patients with HIES. Subsequently, a review on the
vascular features of both autosomal dominant, sporadic
Figure 1 Fine nodules, interstitial infiltrations and a cystic lesion on chest high-resolution computed tomography (HRCT) in a child
with HIES.
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Page 3 of 11Figure 2 High-resolution computed tomography of the chest in a child with HIES, showing aspergilloma in a postinflammatory cavity.
Figure 3 Prognathism in a child with HIES.
Figure 4 Maxillary teeth with severely damaged primary teeth
due to caries as well as carious cavities within permanent
dentition in a child with HIES.
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ried out by Yavuz et al [77]. In AD-HIES patients cor-
onary and aortic aneurysms, thrombosis of the
cerebellar artery and congenital patent ductus venosus
have been identified. In the report by Freeman et al [78]
coronary artery tortuosity or dilation occurred in 70%,
with aneurysms present in 37% of STAT3 mutated HIES
patients, suggesting that STAT3 may play an integral
role in vascular remodeling.
Autosomal recessive HIES
Patients affected with AR-HIES associated with DOCK8
deficiency share certain clinical features with autosomal
dominant HIES, such as newborn rash, eczema and
recurrent upper and lower respiratory tract infections.
Most of the affected patients reported by Zhang et al
[79,80] suffer from recurrent otitis media, mastoiditis,
sinusitis, pneumonias or bronchitis with bronchiectasis.
However, parenchymal lung abnormalities, including
pneumatocele formation have not been observed. Recov-
ered pulmonary pathogens include Streptococcus pneu-
moniae, Haemophilus influenzae, Pneumocystis jiroveci,
adenovirus and respiratory syncytial virus. Mortality is
h i g ha tay o u n ga g ei nA R - H I E Sw i t hs e p s i s ,m o r ef r e -
quent than in AD-HIES [9]. Furthermore, in contrast to
AD-HIES, in autosomal recessive form of the syndrome,
a predisposition to severe fungal and viral cutaneous
infections occurs with herpes simplex and herpes zoster,
molluscum contagiosum and human papillomavirus [80].
An early onset of malignancies, including cancers related
to cutaneous viral infections are an important cause of
death, suggesting impaired tumor surveillance. In five
pediatric patients out of six recorded AR-HIES indivi-
duals, aortic and cerebral aneurysms, underperfusion of
Table 1 Scoring System with Clinical and Laboratory Tests for Related Individuals with HIES
CLINICAL FINDINGS points
0123 45 6 78 1 0
Highest serum-IgE level
(IU/ml)
[Normal < 130 IU/ml]
< 200 200-500 501-1000 1001-2000 > 2000
Skin abscesses None 1-2 3-4 > 4
Pneumonia (episodes over
lifetime)
None 1 2 3 > 3
Parenchymal lung anomalies Absent Bronchiectasis Pneumatocele








Fractures with minor trauma None 1-2 > 2
Highest eosinophil count
(cells/μl)
[700/μl = 1 SD, 800/μl=
2 SD]
<700 700-800 > 800








Newborn rash Absent Present
Eczema (worst stage) Absent Mild Moderate Severe
Upper respiratory infections
per year
1-2 3 4-6 > 6
Candidiasis None Oral Fingernails Systemic
Other serious infections None Severe
Fatal infection Absent Present
Hyperextensibility Absent Present
Lymphoma Absent Present
Increased nasal width < 1 SD 1-2 SD > 2 SD
High palate Absent Present
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iations in the caliber of the basal cerebral arteries, as well
as leucocytoclastic vasculitis were diagnosed [77]. Central
nervous system (CNS) sequelae, in some patients due to
CNS vasculitis, such as facial paralysis, hemiplegia,
ischemic infarction, and subarachnoid hemorrhages are
common and contribute to high mortality. Neither skele-
tal abnormalities, pathological bone fractures, dental dis-




A hallmark of the syndrome is an increased concentra-
tion of immunoglobulin E in the serum, exceeding 2000
U/ml, frequently higher than 5000 U/ml, and in single
cases even exceeding 100 000 U/ml [5,7,34]. A value of
2000 U/ml is considered to be the cut-off point, which
has proved helpful in establishing a definitive diagnosis
of the syndrome [6]. Nevertheless, not in all patients,
particularly in infants, are these criteria fulfilled;
although characteristic concentration of IgE may be
expected in the third decade of life or even later. Typi-
cally in adulthood, in a subset of patients IgE levels may
decrease with age and may fall within a normal range in
about 20% of cases [34]. Interestingly, the severity of
infectious complications in patients with hyper-IgE syn-
drome do not correlate with immunoglobulin E concen-
tration in the serum. Muhammed [81] reported on two
HIES pediatric patients presenting with recurrent cuta-
neous lesions, severe respiratory infections and moder-
ately elevated levels of serum IgE (420 U/ml and 564 U/
ml). This further supports the view that if other features
of HIES are present, a normal IgE level should not
exclude the presence of HIES in older children. Concen-
trations of other main classes of immunoglobulins
remain normal in the majority of cases. Usually blood
eosinophilia coexists, wavering within values at least 2
SD above the normal range (typically higher than 700
cells/microliter) [7,22], not correlating with either the
IgE concentration in the serum or the incidence of
infectious complications.
In the serum, the presence of specific antistaphylococ-
cal and anticandidal IgE antibodies may be revealed
[82,83]; moreover, the increase of antigen specific anti-
bodies may precede the first symptoms of infection [84].
However, the increased concentration of antigen specific
antibodies may also be noted in patients suffering from
atopic dermatitis, rendering the limitation of this test in
the diagnosis of the hyper-IgE syndrome [85].
Heterogeneous disorders of the immune system have
variably been described in HIES patients, including
impaired production of interferon gamma by T cells,
defective T helper 1 (Th1)-dependent cytokine response,
as k e w e dT h 1 / T h 2c e l lr a t i o, a diminished memory T-
cell populations, decreased delayed-type hypersensitivity
responses, an impaired response of lymph cells to anti-
genic and alloantigenic stimulation [86], as well as a
defective neutrophil chemotaxis [3]. However, these
immunological abnormalities do not explain the unique
susceptibility to particular infections seen in HIES.
In 2008, Milner and colleagues [87] demonstrated that
T cells in subjects with AD-HIES failed to produce
interleukin (IL)-17 (but not interferon gamma) after
mitogenic stimulation with staphylococcal enterotoxin B
or after antigenic stimulation with Candida albicans or
streptokinase. Purified naïve T cells were unable to dif-
ferentiate into IL-17 producing the T helper (Th17)
cells in vitro and had a lower expression of the retinoid-
related orphan receptor (ROR)-gt, which is consistent
with the crucial role of STAT3 signaling in the genera-
tion of Th17 cells. These Th17 cells have emerged as an
important subset of helper T cells being critical in the
clearance of fungal and extracellular bacterial infections.
The Th17 cytokines, IL-17 (IL-17A) and IL-17F form
biologically active homo- or heterodimers. Il-17 initiates
nuclear factor kappa B (NF-B) activation, leading to
the transcription of multiple target genes involved in
innate immunity. These include chemokines, such as
CXCL8 (IL-8) and CCL20, the cytokines IL-6, tumor
necrosis factor alpha (TNF-a), granulocyte- and granu-
locyte-macrophage colony-stimulating factor (G-CSF
and GM-CSF, respectively), acute phase proteins such as
C-reactive protein, antimicrobial peptides and mucins
[88]. Thus, IL-17 plays an important role in antimicro-
bial defenses by recruiting and expanding the neutrophil
lineage and producing antimicrobial peptides. The
proinflammatory cytokines produced by Th17 cells
include TNFa, IL-22 and IL-26, which are involved in
innate immunity, and IL-6 which directs CD4+T cells
differentiation towards the Th17 lineage. IL-22 has been
associated with the generation of defensins, acute phase
proteins and inflammatory cytokines [89]. This multidir-
ectional, fundamental role of Th17 cells, including cells
with specificities against candidal antigens explains the
pattern of infection susceptibility characteristic of
STAT3 mutated HIES patients. In the recent report by
Conti et al [90] a decrease of salivary antimicrobial pep-
tides, such as b-defensin 2 and Histatins has been
demonstrated in AD-HIES patients, providing a
mechanism for the severe susceptibility to oropharyngeal
candidiasis. This finding supports this hypothesis of the
crucial role of the Th17-dependent responses in immu-
nity to Candida.
Autosomal recessive HIES
Immune assessments of DOCK8 mutated AR-HIES
patients reveal T cell lymphopenia with low counts of
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expansion from activated peripheral blood mononuclear
cells in vitro. In autosomal recessive HIES eosinophilia
and the elevated serum IgE may be more pronounced
than in AD-HIES [9]. In contrast to the latter syndrome,
DOCK8 deficiency is associated with low IgM concen-
trations and impaired generation of a durable secondary
antibody response to specific antigens, which accounts
for the functional antibody abnormalities [91]. In a sin-
gle patient with AR-HIES due to TYK2 mutation, a nor-
mal number of lymphocytes was observed.
Principles of treatment
The therapeutic strategy in hyper-IgE syndrome is direc-
ted mainly toward the prevention and management of
infections. The introduction of regular long-term intake
of systemic antibiotics and antifungal drugs is of great
importance, as it can prevent serious, overwhelming
infections and prevent lung parenchymal damage. In the
empiric treatment of active respiratory infections, anti-
biotics introduced early on to cover such microorgan-
isms as Staphylococcus aureus, Haemophilus influenzae
and Streptococcus pneumoniae in their spectrum are
recommended. Lung abscesses, which can occur fre-
quently, particularly with staphylococcal pneumonia,
may require surgical intervention. However, frequent
complications after surgery also require particular atten-
tion. An important therapeutic problem as well con-
cerns pneumatocele and bronchiectases, superinfected
with Pseudomonas aeruginosa and other Gram negative
bacteria or with fungi, such as Aspergillus fumigatus;i n
these cases conservative treatment is usually ineffective.
Invasive procedures - resection of the lung parenchyma
limited to pneumatocele or confined bronchiectases are
high-risk therapeutic options due to the reduced ability
of expanding the remaining portion of the lungs [7].
Therefore, in HIES, the decision over the resection of
pneumatocele should be made with particular caution.
In contradistinction to atopic dermatitis in hyper-IgE
syndrome, skin changes frequently improve only after
antibiotic treatment [92]; therefore, intensive antibacter-
ial and antifungal drugs are recommended in the thera-
peutic strategy of cutaneous lesions. Skin abscesses
should be incised and drained. In exacerbations of
eczema caused by the Staphylococcus aureus infection,
apart from topical antibacterial treatment, emollients
and corticosteroids, systemic antibiotic therapy is
recommended as well. In superficial skin and mucosal
candidiasis - onychomycosis, vaginomycosis and oral
thrush treatment with second-generation triazole agents
is effective; moreover, these drugs are also recom-
mended in the treatment of invasive aspergillosis [93].
The use of long-term antibacterial chemotherapy,
including antistaphylococcal activity in its spectrum, e.g.
trimethoprime/sulfamethoxazole, semisynthetic penicil-
lins or cephalosporins, significantly contributes to the
reduction of skin abscesses and staphylococcal pneumo-
nias [7,94]. The development of resistance in the course
of long-term therapy outweighs the risk of severe infec-
tions and lung damage when it is discontinued [7]. The
administration of immunoglobulins is controversial.
Kimata et al [95] reported positive results of high-dose
intravenous immunoglobulins, leading to the decrease in
IgE concentration and in effective protection against
severe infections. Even if the concentration of IgG is
within the normal parameters for the age range, defi-
ciency of IgG subclasses or lack of specific post-vaccina-
tion antibodies are observable. Consequently, the
introduction of regular immunoglobulin substitution
seems to be of great value; however, some authors did
not note any positive effect in the use of this treatment
[96]. In HIES some positive clinical effects [97], as well
as an improvement of the neutrophil chemotactic func-
tion assessed in vitro [98], were achieved during prophy-
lactic treatment with H2-receptor antagonists.
Improvements in neutrophil phagocytosis and in
respiratory burst were also noted with the use of sodium
cromoglycate [99,100]. Poor effects of levamisole therapy
reported by Donabedian [101] do not warrant its use in
the case of the hyper-IgE syndrome. On the contrary,
synthetic vitamin A derivative - isothretinoine proved to
be effective in the treatment of cutaneous complications
[102].
In vitro studies revealed an improvement in the neu-
trophil chemotactic function with IFN-g [103], yet clini-
cal observations point to the lack of a long-term effect
on IgE concentration and on episodes of infection in
patients with HIES [104]. Moreover, in one patient who
was on interferon therapy, autoimmune thrombocytope-
nia was noted [105]. Reports concerning the use of
cyclosporine A are encouraging; a positive clinical effect
was observed by Wolach [106] and Etzioni [107]. Ishi-
kava et al [108] and other investigators [23,109] noted
an improvement after plasmapheresis. Currently, there
is a lack of data associating therapeutic benefits with
monoclonal anti-IgE antibody (omalizumab); the
required high dose for neutralization of immunoglobulin
E appears to exclude its clinical application. Attempts at
hematopoietic stem cell transplantation (HSCT) also
have been undertaken. Preliminary studies did not con-
firm the efficacy of this procedure [110,111], albeit
further reports showed successful immunologic reconsti-
tution in patients with both autosomal dominant [112]
and autosomal recessive hyper-IgE syndrome [113-115].
Particularly in the latter form of HIES due to DOCK8
deficiency, HSCT should be considered early on before
the development of life-threatening complications,
including malignancies [113].
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A scoring system comprising both clinical and labora-
tory diagnostic criteria has been proposed by Grimba-
cher and colleagues and accepted by the National
Institute of Health (NIH) [116] (table 1). An analysis,
carried out on the basis of this scale and reaching the
particular total score, indicates that the affected indivi-
dual is probably a carrier of the hyper-IgE genotype, or
t h a tt h ep r e s e n c eo ft h i sg e n o t y p ei su n c e r t a i n ,o r ,a t
the very least, is less likely. However, several symptoms
like scoliosis, a characteristic face, or delayed loss of pri-
mary teeth can not be taken into account in children
under the age of eight, since they may not occur until
adolescence. Likewise, the number of episodes with
infections, bone fractures and pulmonary disorders lead-
ing to the development of pneumatocele increases with
age. Therefore, in the scoring system, the age intervals
of the occurrence of particular symptoms have been
included. The assessment of the suspected patient
according to this scoring system and the gaining ≥ 15
points makes the recognition of hyper-IgE phenotype
highly probable. The diagnostic approach proposed
recently by Schimke and colleagues confirmed that the
NIH scoring system accurately identifies patients with
HIES [117].
Genetic testing
T h em a j o r i t yo fp a t i e n t sw i t hA D - H I E Sh a v eh e t e r o z y -
gous STAT3 mutations in the DNA-binding and Src
homology 2 (SH2) domains [14,15]. All mutations are
hypomorphic - missense mutations or in-frame deletions
- and involve only one allele of STAT3, which suggests a
dominant-negative effect. However, these mutations are
found only in a limited number of patients with incom-
plete clinical features [16,57]. This observation is sup-
ported by Al Khatib et al [118], indicating molecular
heterogeneity of the disease and suggesting that other
potential gene defects may be functionally linked to
STAT3. Recently, diagnostic criteria for STAT3-deficient
individuals with clinical suspicion of HIES were pro-
posed by Woellner and colleagues [119]. The following
characteristics - total IgE concentration > 1000 IU/ml
and weighted score of clinical features > 30 (based on
recurrent pneumonias, newborn rash, pathologic bone
fractures, characteristic face and high palate) plus a
dominant-negative heterozygous mutation in STAT3 -
allow for a definitive diagnosis.
Homozygous mutations in DOCK8, causing premature
termination, frameshift, splice site disruption, single
exon deletions and microdeletions were found in many,
although not all, patients with autosomal recessive
hyper-IgE syndrome [19]. To date, a single patient with
a clinical diagnosis of AR-HIES was identified with a
homozygous TYK2 gene mutation. This suggests that
other genes may also result in the autosomal recessive
form of HIES [18].
Concluding remarks
The hyper-IgE syndrome, a multisystemic disorder with
a broad constellation of clinical manifestations, is a
great challenge for clinicians in establishing a diagnosis
in suspected cases. HIES seems to be not a sole disease
but rather a group of similar diseases with heterogeneity
of underlying genetic defects. Patients with the hyper-
IgE syndrome require interdisciplinary care by specialists
in pediatrics/internal medicine, pneumonology, derma-
tology, surgery, stomatology, neurology, oncology, and
psychology under the clinical immunologist’s
supervision.
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